The central tools of the study were expression quantitative trait loci, or eQTLs. An eQTL is a genetic variant that correlates with the expression level of a particular gene, effectively serving as a naturally occurring experiment in gene regulation. Most large-scale eQTL catalogs, however, are built from cells sampled at rest, in what researchers call a steady state. For immune cells, that is a biologically artificial situation. CD4+ T cells are the conductors of the adaptive immune response, and in asthma they orchestrate airway inflammation through specialized lineages such as Th2 cells, which drive the allergic responses characteristic of much of the disease burden, as well as Th17 and T follicular helper cells. When a naive CD4+ T cell encounters antigen and becomes activated, it reprograms its transcriptional landscape, its signaling networks, and its epigenetic architecture. A variant that strongly controls a gene in a resting cell may be functionally silent in an activated effector cell, and vice versa.

To test whether this matters for asthma genetics, the team integrated activation-resolved eQTL data covering multiple stages of CD4+ T-cell activation with two independent statistical frameworks. The first was two-sample Mendelian randomization, a technique that uses genetic variants as instrumental variables to ask whether altered expression of a gene causally influences a disease outcome, rather than merely co-occurring with it. The second was genetic colocalization, which tests whether an association signal for gene expression and an association signal for disease risk in the same genomic region are driven by the same causal variant. Together, these methods filter the noisy universe of statistical correlations down to a smaller set of genes whose regulation is plausibly and specifically linked to asthma through shared genetic mechanisms. The asthma evidence came from genome-wide association study summary statistics, allowing the entire analysis to run on aggregated, de-identified data without any new human sampling.

The scale of the screen was substantial. Across 7,295 genes, the researchers performed 34,266 Mendelian randomization tests spanning the different activation stages. Of these, 316 genes showed significant genetic support for a causal relationship with asthma risk, and 278 of those were further backed by colocalization evidence, meaning the same variant could plausibly explain both the altered gene expression and the altered disease risk. The striking result was where these signals appeared. Genetically supported associations were far more frequent at intermediate and late stages of T-cell activation, and the majority were confined to a single activation state. A static, resting-cell eQTL catalog simply could not see most of them.

The contrast with conventional resources was quantified directly. The researchers benchmarked their activation-resolved approach against four widely used static eQTL datasets, drawn from the OneK1K, DICE, GTEx, and eQTLGen consortia. Under the study’s criteria, 163 of the 278 colocalization-supported genes, or 58.6 percent, emerged only from the activation-resolved analysis. That is not a marginal improvement; it means the majority of genetically credible asthma regulatory signals detectable in activated T cells were invisible to the standard reference maps that much of human genetics relies upon. The pattern was not uniform across T-cell biology either. The prioritized genes were enriched in activated and effector CD4+ T-cell subsets, with particularly strong representation in the CD4_STIM activated population and in Th2, T follicular helper, and Th17 lineages, each of which has well-established roles in asthmatic airway inflammation.

The team also examined how regulatory effects behaved across activation stages and found recurring temporal profiles. Some genes showed sustained regulatory influence across all stages, while others displayed what the authors call direction-switch patterns, in which the same genetic variant pushes gene expression up in one activation state and down in another. This heterogeneity has real implications. It suggests that the genetic architecture of asthma risk is not a fixed property of a gene but a dynamic property of a gene within a cellular context, and that collapsing all states into a single average can both dilute genuine signals and obscure effects that reverse direction. The researchers were careful, however, to frame these findings appropriately: the patterns reflect differences in genetically supported associations across activation states, not direct proof that causal effects change over time in living patients.

Independent validation strengthened the case. Using summary statistics from the Global Biobank Meta-analysis Initiative, the team re-tested 787 primary Mendelian randomization-supported cell-state and gene pairs. A total of 477 pairs, 60.6 percent, were replicated in the external dataset, and of the replicated pairs 97.1 percent showed effect directions consistent with the original analysis. That degree of directional concordance is reassuring, because replication with flipped effect directions would have suggested unstable or spurious findings. Instead, it indicates that activation-resolved eQTL signals linked to asthma are robust across independent cohorts of European ancestry.

The translational payoff of the study is a structured shortlist of 47 candidate genes for drug development. Priority was assigned by combining the genetic evidence with existing drug-target databases and clinical evidence. Notably, seven of the candidates already have links to asthma-related clinical trials, providing an immediate sanity check on the pipeline, while others carry potential relevance for drug repurposing, meaning existing medicines aimed at those targets could be evaluated in asthma with a head start on safety data. Genes supported both by human genetics and by existing pharmacology are widely regarded as the highest-yield starting points for drug discovery, because human genetic validation substantially raises the probability that modulating a target will produce clinical benefit.

The study also probed why activation-specific signals exist at all. The analysis showed that greater CD4+ T-cell specificity of a gene was associated with increased odds that its regulatory signal was restricted to a particular activation stage, with an odds ratio of 1.18 per unit increase, a 95 percent confidence interval of 1.11 to 1.25, and a P value of 1.4 times ten to the minus seventh, surviving correction for multiple testing. In plain terms, genes whose expression is highly specialized to CD4+ T cells are more likely to show activation-context-dependent regulation, which fits the biology of immune cells whose identity is defined by state-specific transcriptional programs.

Important caveats accompany the findings. The eQTL and GWAS resources underlying the work were derived predominantly from individuals of European ancestry, so generalizing the prioritized targets to other populations will require additional datasets. Mendelian randomization and colocalization, powerful as they are, operate on summary statistics and indirect genetic instruments, and their conclusions are only as good as the assumptions underlying those instruments. Even so, the broader message is likely to reshape how immunogeneticists approach complex disease. The study demonstrates that the cellular state in which gene regulation is measured is not a technical detail but a first-order determinant of what genetic association studies can find. For asthma, a disease whose immunology is defined by activated effector T cells, resting-state reference maps have been effectively photographing the wrong moment. Activation-resolved eQTL atlases, the authors argue, should be treated as complementary and essential resources, and the 47-gene shortlist they produce offers drug developers a genetically grounded place to look next.

Subject of Research: Activation-resolved eQTL and Mendelian randomization analysis of CD4+ T-cell genetic regulation in asthma

Article Title: Activation-dependent genetic regulation in CD4⁺ T cells prioritizes druggable targets for asthma

Article References: Yan, Q., Liu, D., Yan, L., Wang, J., Li, L., Tan, L., Li, D., Nie, J., & Luo, J. (2026). Activation-dependent genetic regulation in CD4⁺ T cells prioritizes druggable targets for asthma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09033-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09033-w

Keywords: asthma, CD4+ T cells, eQTL, Mendelian randomization, colocalization, GWAS, drug target prioritization, gene regulation, immunogenetics, T-helper cells, translational medicine, Activation-dependent

The MHC is the molecular gatekeeper of vertebrate adaptive immunity. Its class IIB genes encode cell-surface receptors that grab fragments of invading parasites and present them to immune cells, triggering the response that ultimately clears an infection. Because parasites constantly evolve to evade this surveillance, MHC genes are among the most polymorphic in the vertebrate genome, and decades of research have documented how this sequence diversity is shaped by parasite-mediated selection within and among populations. But sequence is only part of the story. An allele that is transcribed at high levels presents many more antigen fragments than an allele transcribed at low levels, meaning that two alleles with identical binding properties could still differ functionally simply because of how actively they are expressed. The new study set out to measure exactly that: allele-specific expression of MHC class IIB genes in wild cichlid populations, and how that expression relates to allele frequency, functional supertypes, and population structure.

The researchers, led by Seraina E. Bracamonte of the Museo Nacional de Ciencias Naturales in Madrid and Uppsala University, together with Pascal I. Hablützel, Carlos Lozano-Martín and Marta Barluenga, built on previous work showing that MHC class IIB diversity is associated with ecological divergence in cichlid fish. Midas cichlids, which inhabit multiple Nicaraguan crater lakes and have repeatedly adapted to different habitats within and among those lakes, offer an ideal natural laboratory for asking how immune genes vary across populations that occupy distinct selective environments. Using quantitative PCR-based approaches to measure how much of each allele’s transcript was present in individual fish, the team generated expression profiles for the MHC alleles carried by wild-caught animals, and then compared those profiles with allele frequencies and with the functional supertypes to which each allele had previously been assigned.

The results were striking. A handful of highly abundant alleles, those found in a large proportion of individuals across populations, turned out to be consistently expressed at low levels. Meanwhile, many of the rarer alleles were expressed at high levels and, crucially, were restricted to particular host populations. In other words, the most common versions of the gene were the quietest, while the loudest versions of the gene were the rarest and the most geographically localized. This inverse relationship between allele frequency and expression is the kind of pattern that immediately suggests an evolutionary explanation, although the authors are careful to note that the mechanism remains to be demonstrated. It could reflect a trade-off in which broadly shared alleles perform a generalist function at low cost, while population-specific alleles provide specialized defense against local parasites and are maintained at high expression where those parasites occur.

Expression also tracked functional supertypes, the groupings of MHC alleles that share similar antigen-binding properties despite differing in sequence. Alleles belonging to the same supertype showed similar expression patterns, which means that the functional units of MHC diversity, the supertypes rather than individual alleles, appear to be regulated in a coordinated fashion. Even more intriguing was the pattern across populations: supertypes with low expression showed relatively consistent expression everywhere they occurred, while highly expressed supertypes exhibited substantially greater variation among populations. This suggests that the most functionally conspicuous components of the immune repertoire are also the ones most sensitive to local conditions, consistent with the idea that different lakes and habitats impose different parasite pressures and that expression, not just sequence, is part of the local adaptation story.

To test whether these patterns were unique to Midas cichlids or a general feature of the family, the team turned to African cichlids, the most species-rich vertebrate radiation on Earth and the evolutionary cousins of the Nicaraguan fish. In the African dataset, putative MHC class IIB loci also showed marked variation in expression, indicating that allele- and locus-specific expression differences are not a quirk of one lineage but a recurring feature of cichlid immunogenetics. The comparison across continents produced the study’s most unexpected finding: when the researchers placed all the alleles and loci into a phylogenetic tree, the lowly expressed Midas cichlid alleles clustered together with the lowly expressed putative African loci, while most highly expressed variants formed separate clusters. Expression level, in other words, appears to track deep evolutionary lineages, hinting that low expression may be an ancient property of particular MHC lineages rather than a recent adjustment to local conditions.

The phylogenetic association raises fascinating questions about the origins and maintenance of expression diversity. If low expression is tied to distinct MHC lineages that have persisted across tens of millions of years of cichlid evolution and across an ocean, then expression differences may be deeply embedded in the genome, perhaps reflecting regulatory divergence that arose early in the family’s history and has been inherited ever since. Alternatively, similar selective pressures acting independently on both continents could have produced the same association between lineage and expression level. The authors are explicit that the functional significance of these patterns remains unresolved. Whether lowly expressed lineages perform different immunological roles, whether they are subject to different regulatory control, or whether their low expression is itself adaptive, cannot yet be determined from expression data alone.

What the study does establish is that MHC diversity cannot be fully captured by sequencing alone. Immunogeneticists have long recognized that the number of MHC alleles an individual carries, and the functional diversity of those alleles, shape disease resistance. The new findings add a third axis: how much each allele is actually transcribed. An individual carrying a high-diversity MHC repertoire in its genome may express only a subset of those alleles at meaningful levels, effectively narrowing its functional antigen-presenting capacity. Conversely, population-level comparisons based purely on allele frequencies may miss the fact that the same allele can behave differently in different populations, as the among-population variation in highly expressed supertypes demonstrates. For studies of local adaptation, host-parasite coevolution, and even conservation genetics of endangered fish populations, incorporating expression measurements could change the interpretation of MHC data substantially.

The path forward, the authors emphasize, lies in connecting expression to phenotype. The study was conducted on wild fish without direct parasite and infection data, so the critical next step is to test whether the observed expression patterns actually influence parasite recognition and resistance, and whether parasite-mediated selection shapes expression as it demonstrably shapes sequence. If it does, then the hidden layer of MHC diversity documented here may prove to be a key ingredient in the extraordinary adaptive radiation of cichlids, the same evolutionary process that has filled African lakes with hundreds of species and Nicaraguan crater lakes with repeated pairs of lake- and stream-adapted forms. For now, the message is clear: in the immune genes of cichlids, how loudly a gene speaks matters as much as what it says, and evolution has been listening to both.

Subject of Research: Allele-specific expression variation of MHC class IIB genes in wild cichlid fish populations

Article Title: Expression diversity of cichlid MHC alleles

Article References: Bracamonte, S. E., Hablützel, P. I., Lozano-Martín, C., & Barluenga, M. (2026). Expression diversity of cichlid MHC alleles. BMC Genomics. https://doi.org/10.1186/s12864-026-13370-x

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13370-x

Keywords: MHC, cichlids, gene expression, immunogenetics, host-parasite interactions, local adaptation, Midas cichlid, functional supertypes, BMC Genomics, evolutionary biology, allele frequency, population genetics

Unlike influenza A, influenza B virus lacks a broad animal reservoir and, with it, the pandemic potential that makes influenza A a constant global security concern. But the absence of pandemic risk has never equated to clinical irrelevance. Influenza B virus drives substantial morbidity in seasonal epidemics, and its two historically circulating lineages, B/Victoria and B/Yamagata, have followed strikingly different trajectories in recent years. Surveillance has documented no confirmed naturally circulating B/Yamagata-lineage viruses since March 2020, a development widely linked to the intense non-pharmaceutical interventions of the COVID-19 pandemic era. Current influenza B activity is now overwhelmingly attributable to B/Victoria-lineage viruses, a shift with real consequences for vaccine composition and the interpretation of vaccine effectiveness studies.

The central premise of the review is that the host genome may help explain a persistent puzzle: why individuals exposed to the same virus, and receiving the same vaccine, experience markedly different outcomes. Variation in genes governing antigen presentation, innate viral sensing, interferon signaling, and host dependency or restriction factors could plausibly generate heterogeneity in susceptibility, disease severity, cross-lineage immunity, and responsiveness to immunization. This framework draws on decades of immunogenetic research in influenza A and in broader antiviral biology, but the authors stress a crucial caveat: much of what has been proposed for influenza B rests on inference rather than on direct, influenza B virus-specific human data.

At the heart of the immunogenetic hypothesis lies the human leukocyte antigen system, the protein complex responsible for presenting viral peptide fragments to T cells. Differences in HLA alleles can alter which viral epitopes are displayed, how strongly T cells respond, and consequently how efficiently an infected or vaccinated individual clears virus or mounts protective memory. For influenza A, associations between specific HLA variants and outcomes such as infection risk, severity, and antibody titers after vaccination have been reported across multiple populations. Extending these findings to influenza B is not straightforward, however, because the two virus types differ in their evolutionary dynamics, transmission patterns, and the antigenic landscape they present to the immune system. Epitope repertoires are not interchangeable, and a genetic variant that enhances clearance of one influenza type may have little or no measurable effect on the other.

Beyond antigen presentation, the review considers the innate immune machinery that first detects invading influenza viruses. Pattern recognition receptors such as the toll-like receptors and RIG-I-like receptors sense viral RNA and trigger signaling cascades that culminate in interferon production. Genetic polymorphisms in these sensors and in the downstream interferon pathway can modulate the vigor of the early antiviral response, potentially determining whether an infection is contained quickly or gains a foothold. Similarly, host dependency factors that the virus requires for entry, replication, and assembly, along with restriction factors that actively inhibit viral replication, represent additional layers where inherited variation could shape susceptibility. Each of these domains offers a plausible mechanistic route by which host genotype could influence influenza B outcomes, yet the authors find that direct evidence in the influenza B context remains sparse and fragmentary.

When it comes to vaccine response, the review is similarly measured. The best-supported determinants of influenza vaccine performance, the authors conclude, are not genetic at all. Antigenic match between vaccine strains and circulating viruses, the continuous process of antigenic drift that erodes that match over time, the age of the vaccinee, prior exposure history, and baseline immunity stand out as the factors with the strongest evidentiary grounding. These non-genetic determinants have been repeatedly validated across seasons and populations, and they explain a considerable portion of the year-to-year variability in vaccine effectiveness. Genetic predictors specific to influenza B, by contrast, remain incompletely defined, and no validated host-genetic biomarker currently exists to guide vaccination decisions for this virus.

This asymmetry between well-established extrinsic factors and poorly characterized intrinsic ones is not merely an academic gap. Predictive models of influenza B immune control and vaccine performance are limited by the absence of genotype-linked outcome data. Without large, well-phenotyped cohorts in which host genotype, immune phenotyping, and lineage-resolved virologic outcomes are collected together, the field cannot distinguish genuine genetic effects from confounding by age, prior exposure, or antigenic distance. The authors argue that such integrated studies represent the most important priority for future research, and they outline a research agenda built around linking these data streams in a single analytical framework.

The disappearance of the B/Yamagata lineage adds an unusual wrinkle to this agenda. With no naturally circulating Yamagata viruses detected for years, vaccine components targeting that lineage have become biologically obsolete, and regulatory and advisory bodies have been reconsidering the composition of seasonal vaccines, including the transition from quadrivalent to trivalent formulations. For immunogenetic studies, the loss of a circulating lineage complicates the interpretation of historical cross-lineage immunity data and underscores the need for lineage-resolved outcome measures in future cohorts. Any genetic association study conducted today will, in practice, be measuring responses against B/Victoria viruses, and generalizing those findings to influenza B as a whole carries inherent uncertainty.

Population-specific variation presents another challenge. Immunogenetic associations identified in one ancestry or geographic setting frequently fail to replicate elsewhere, reflecting both genuine differences in allele frequencies and differences in study design, exposure patterns, and co-circulating pathogens. The international composition of the review team, spanning institutions in China, Pakistan, and Uzbekistan, reflects a growing recognition that influenza B research must extend beyond the settings where it has traditionally been studied. Building the evidence base for immunogenetic determinants will require multi-center collaborations with standardized genotyping platforms, harmonized immune phenotyping protocols, and consistent definitions of susceptibility, severity, and vaccine response.

The review, which received support from the Guangdong Basic and Applied Basic Research Foundation and the Dongguan Science and Technology of Social Development Program, ultimately delivers a message of disciplined optimism. The biological logic connecting host genetic variation to influenza B outcomes is sound, and the methodological tools needed to test it, from affordable genome sequencing to sophisticated immune profiling, are now widely available. What is missing is the concerted, influenza B-specific data collection that would convert plausible mechanisms into clinically actionable knowledge. Until that work is done, antigenic match, age, and exposure history will remain the most reliable predictors of how influenza B behaves in populations, while the genome’s contribution waits to be quantified.

Subject of Research: Immunogenetic determinants of influenza B virus susceptibility and vaccine response

Article Title: Immunogenetic determinants of influenza B virus susceptibility and vaccine response: current evidence, gaps, and future directions

Article References: Din, G. U., Khan, H., Tariq, Z., Zhao, J., Khan, A., Eshboev, F., Xu, G., Hu, Y., & Huang, K. (2026). Immunogenetic determinants of influenza B virus susceptibility and vaccine response: current evidence, gaps, and future directions. Virology Journal. https://doi.org/10.1186/s12985-026-03292-1

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03292-1

Keywords: influenza B virus, immunogenetics, host susceptibility, vaccine response, immune heterogeneity, antigenic drift, HLA, interferon, B/Victoria lineage, B/Yamagata lineage, Immunogenetic, determinants

IgG4-related disease is characterized by tumor-like infiltrates rich in IgG4-positive plasma cells, storiform fibrosis, and elevated serum IgG4 concentrations. Patients frequently present with IgG4-related autoimmune pancreatitis, in which the pancreas becomes swollen and rigid, or with Mikulicz disease, marked by painless enlargement of the salivary and lacrimal glands. Although the pathology is well described, the initiating events have been poorly understood. Proposed mechanisms range from autoantibody production to aberrant cytotoxic T lymphocyte activity, yet the triggers that set the immune system on its characteristic type 2 trajectory remain uncertain. Intriguingly, trypsin has been used for decades as an adjunctive therapy for chronic inflammatory and autoimmune conditions, a clinical tradition that made the enzyme’s gene an unexpected but thought-provoking candidate when variants began appearing in the sequencing data.

The research team, led by investigators at the First Affiliated Hospital of Fujian Medical University, applied whole-exome sequencing to affected tissue samples from three patients: two with IgG4-related autoimmune pancreatitis and one with Mikulicz disease. This approach reads the protein-coding regions of the genome in exhaustive detail, allowing rare variants to be detected directly in diseased tissue. Among the mutations surfaced in the analysis, the p.Lys70Asn and p.Phe73Leu changes stood out because both alter amino acids within trypsinogen, potentially modifying the protein’s folding, activation, or stability. Because these variants were identified in lesion tissue rather than blood alone, they may reflect changes present in the affected organs themselves, raising the possibility that altered trypsinogen biology contributes locally to disease development.

Equally important was what the researchers observed when they examined the cellular composition of the affected tissues. Histological and transcriptional analysis revealed activation of M2 macrophages, the anti-inflammatory, tissue-repair-oriented members of the macrophage family. Macrophages are not a uniform population; classically activated M1 macrophages drive antimicrobial inflammation, while alternatively activated M2 macrophages promote wound healing, fibrosis, and type 2 immune responses through cytokines such as transforming growth factor beta and interleukins. In IgG4-related disease, an overabundance of M2 activity could explain two hallmark features at once: the exuberant fibrosis that hardens affected organs and the Th2-skewed immune environment that drives B cells to class-switch toward IgG4 production. Prior work by other groups had already implicated interleukin-33 produced by M2 macrophages in the Th2 reaction of IgG4-related disease, lending plausibility to the new observations.

To place these findings in a higher-resolution context, the team integrated single-cell RNA sequencing datasets with spatial transcriptomic analysis of pancreatic tissue from the mutation-positive cases. Single-cell RNA sequencing dissects a tissue into its constituent cell types and profiles gene expression in each one, while spatial transcriptomics preserves the geographic information, revealing which cell populations sit next to which structures within the intact organ. Combining the two techniques allowed the researchers not only to catalog the immune cells infiltrating the pancreas but also to map their physical relationships. This spatial map showed that M2 macrophage-derived molecules, including TGF-beta, occupy positions consistent with a role in promoting type 2 immune responses within the lesion microenvironment, effectively linking the cellular census to the architectural reality of the diseased tissue.

The mechanistic picture that emerges is a plausible multi-step model. Variants such as p.Lys70Asn and p.Phe73Leu may perturb trypsinogen handling in pancreatic or glandular tissue, creating local stress or altered proteolytic signaling. That perturbation could favor recruitment and polarization of macrophages toward the M2 state. Once established, M2 macrophages would secrete TGF-beta and other mediators that sculpt the immune milieu toward Th2 dominance, encouraging IgG4 class-switching in B cells and the fibrotic remodeling that characterizes the disease. The authors conclude that these novel PRSS1 variants may contribute to the pathogenesis of IgG4-related disease by activating type 2 immune responses, a formulation that positions trypsinogen genetics upstream of the immunological cascade rather than as a bystander.

The study carries several caveats worth noting. The sequencing cohort comprised only three patients, a sample size dictated by the rarity of the disease and the difficulty of obtaining affected tissue, so the prevalence of the PRSS1 variants in the broader IgG4-related disease population remains unknown. The evidence connecting the variants to macrophage polarization is associative, drawn from tissue analysis and transcriptomic correlation rather than from direct functional experiments demonstrating that the mutant trypsinogen induces M2 skewing. Future work will need to reproduce the findings in larger cohorts, test the variants in cellular and animal models, and determine whether the mutations are inherited, somatic, or arise through other mechanisms. The data underlying the study are available from the corresponding author upon reasonable request, and the work was approved by the Medical Ethics Committee of the First Affiliated Hospital of Fujian Medical University with written informed consent from all participants.

Even with those limitations, the implications are considerable. If PRSS1 variants indeed seed the type 2 immune environment of IgG4-related disease, they could serve as biomarkers for identifying patients at risk or for classifying disease subtypes. More ambitiously, they point toward interventions that target the trypsinogen-macrophage axis, whether through modulating protease activity, dampening M2 polarization, or intercepting TGF-beta signaling. The findings also resonate with a long clinical curiosity: trypsin’s historical use as an anti-inflammatory therapeutic. Understanding how trypsinogen variants behave in disease tissue may eventually clarify when protease-based approaches help and when they might be counterproductive.

For a disease that has long defied simple explanation, the Fujian team’s work adds a concrete genetic and cellular thread to the story. By uniting whole-exome sequencing, single-cell transcriptomics, and spatial mapping in the same patients, the study demonstrates how modern multi-omics tools can convert rare clinical specimens into mechanistic hypotheses. The discovery that trypsinogen isoforms and variants may promote type 2 immune responses in IgG4-related disease does not close the case on this enigmatic condition, but it opens a well-defined line of investigation, one that traces the path from a DNA sequence change to an immune microenvironment and, ultimately, to the fibrotic organ damage that patients experience.

Subject of Research: Novel PRSS1 trypsinogen gene variants and their role in type 2 immune responses in IgG4-related disease

Article Title: PRSS1 isoforms promote type 2 immune responses in IgG4-related disease

Article References: PRSS1 isoforms promote type 2 immune responses in IgG4-related disease. (n.d.). https://doi.org/10.1038/s41435-026-00412-3

Image Credits: AI Generated

DOI: 10.1038/s41435-026-00412-3

Keywords: IgG4-related disease, PRSS1, trypsinogen, M2 macrophages, type 2 immune response, autoimmune pancreatitis, Mikulicz disease, whole-exome sequencing, single-cell RNA sequencing, spatial transcriptomics, TGF-beta, immunogenetics

The expectations were not arbitrary. Genes involved in allorecognition, the ability to distinguish self from non-self among members of the same species, are classically assumed to be driven by balancing selection, the evolutionary force that maintains many different versions of a gene within a population. This pattern is abundantly documented in the major histocompatibility complex of vertebrates, in fungal heterokaryon incompatibility loci such as het-c, in plant self-incompatibility systems, and in the allorecognition genes of hydroids and sponges. Under this model, rare alleles enjoy a selective advantage, frequency-dependent dynamics keep many variants circulating, and the protein products of the gene diversify into ever more distinctive forms, each tuned to recognize a different repertoire of non-self partners. When the researchers set out to characterize BHF across natural and laboratory populations of B. schlosseri, they anticipated finding precisely these signatures.

Instead, they found something stranger. The team analyzed full-length BHF alleles from nineteen colonies, drawn both from laboratory-born stocks and wild populations, and uncovered thirty-three distinct alleles. At the DNA level, the locus is a riot of variation: nucleotide diversity is pronounced, alleles vary extensively in length, and the genealogy of the sequences shows clear evidence of intragenic recombination, with different segments of the gene telling contradictory evolutionary stories. Yet when the researchers translated the alleles into their protein products, the picture collapsed into remarkable uniformity. Those thirty-three alleles encode only seventeen distinct protein variants. The explosive divergence seen in the nucleotide sequence is largely silent at the level of the protein, a pattern that immediately suggested strong functional constraints keeping the encoded molecule stable even as its underlying blueprint drifts.

The geographic distribution of these alleles added another layer of intrigue. Highly divergent alleles, sequences so different from one another that they appear to have separated in the distant past, tend to coexist within the same individual colony, a hallmark of long-lived polymorphism. At the same time, identical alleles were found to be shared across continental-scale distances, a pattern difficult to reconcile with purely local evolution. In a species whose larvae disperse only over short ranges, such global allele sharing points to movement mediated by humans: B. schlosseri is a notorious fouling organism that hitches rides on ship hulls and in ballast water, and previous work by the same group and others has shown that historical navigation routes have left detectable footprints on the species’ seascape genetics. The new findings suggest that this human-mediated gene flow has effectively homogenized BHF alleles across ocean basins, mixing variant repertoires that might otherwise have diverged in isolation.

To probe the evolutionary forces at work, the researchers subjected the allele alignments to a battery of statistical tests designed to detect natural selection at individual codons. Contrary to the predictions of the diversifying-allele model, no evidence of balancing selection or directional positive selection emerged from the analyses. What the tests did reveal were signatures of purifying selection, the process by which natural selection removes harmful mutations and conserves protein function. In other words, the vast majority of the nucleotide variation in BHF is either silently synonymous or otherwise constrained from changing the protein it encodes, and the few amino-acid substitutions that do occur appear tolerated only within narrow limits. For a gene whose job is, by definition, to discriminate among an enormous diversity of non-self surfaces, this conservation of protein structure is genuinely counterintuitive.

The authors propose that the peculiar contrast between nucleotide and protein diversity at BHF arises from the combined effects of several processes acting simultaneously. Intragenic recombination continually shuffles DNA segments between alleles, generating new nucleotide combinations and inflating sequence diversity without necessarily altering protein sequences, particularly when crossovers occur in regions where the variants are functionally equivalent or where synonymous sites dominate. Human-mediated transport spreads the resulting allele repertoire globally, ensuring that any given colony can harbor partners for its most divergent alleles. Meanwhile, linkage to nearby loci that genuinely are under balancing selection could drag neutral and nearly neutral variation at BHF along for the ride, inflating apparent diversity at the locus without any direct selective diversification of the gene itself. This hitchhiking scenario echoes mechanisms documented in other systems, where polymorphisms maintained at one gene cast a long shadow of diversity across adjacent regions of the genome.

The technical groundwork for the study rested on methods refined over decades of research into the B. schlosseri fusion-rejection system, first described genetically by Abe Sabbadin in 1962 and later linked to a MHC-like gene system by Scofield and colleagues in 1982. The chromosomal location of the histocompatibility locus was resolved in 2005 by De Tomaso and coworkers, and the identity of BHF itself was established by Voskoboynik and colleagues in a landmark 2013 Science paper. Recombination analysis in the new study employed modern tools including RDP5, which screens sequence data for exchange events using multiple independent detection algorithms, while tests of codon-specific selection drew on maximum-likelihood frameworks that estimate synonymous and non-synonymous substitution rates across the gene. Exon- and intron-based phylogenies were compared to expose topological incongruence, the fingerprint of recombination, and predicted pairwise interaction outcomes were modeled on the assumption that colonies sharing at least one protein allele would fuse.

The broader significance of the finding extends beyond a single marine invertebrate. If extensive protein diversification is not a universal driver of allorecognition gene evolution, then the textbook equation of self/non-self recognition systems with runaway diversifying selection may need qualification. It raises the possibility that some recognition systems achieve functional diversity through means other than amino-acid innovation, for instance through the combinatorial pairing of a modest set of protein variants, or through differences in expression and regulation that are invisible to sequence-based analyses. It also cautions researchers studying other invertebrate allorecognition loci, from the Alr genes of hydroids to the aggregation factors of sponges, against assuming that polymorphism at the nucleotide level necessarily translates into adaptive protein diversification, since recombination, demographic mixing and linkage can each generate misleading signals.

For the field of comparative immunology, the BHF locus remains an indispensable touchstone precisely because it sits at the boundary between innate and adaptive immunity, in an organism whose blood-forming system has recently been shown to resemble that of mammals in surprising complexity. The new work does not diminish the gene’s predictive power over fusion and rejection; it simply reframes how that power is maintained. Purifying selection, recombination, and a globe-trotting lifestyle, it turns out, can conspire to keep a recognition gene both endlessly variable in its DNA and stubbornly conservative in its protein, a combination that ensures B. schlosseri will continue to puzzle and instruct immunologists for years to come.

Subject of Research: Evolutionary genetics of the Botryllus histocompatibility factor allorecognition locus in the colonial tunicate Botryllus schlosseri

Article Title: Intra-colony divergence and global allele sharing reflect purifying selection and recombination at the Botryllus histocompatibility factor locus

Article References: Intra-colony divergence and global allele sharing reflect purifying selection and recombination at the Botryllus histocompatibility factor locus. (n.d.). https://doi.org/10.1007/s00251-026-01413-2

Image Credits: AI Generated

DOI: 10.1007/s00251-026-01413-2

Keywords: Botryllus schlosseri, allorecognition, BHF, purifying selection, intragenic recombination, histocompatibility, tunicate immunity, balancing selection, polymorphism, self/non-self recognition, immunogenetics, gene flow